Oma Fertility vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Oma Fertility operates affordable mini IVF clinics using a lower-stimulation protocol that reduces medication costs and side effects, making IVF accessible to more patients.
About
Oma Fertility is a fertility clinic company founded in 2019 that operates a network of fertility clinics using minimal stimulation IVF (mini IVF) as a primary treatment approach, offering IVF at significantly lower cost than conventional high-stimulation protocols. Mini IVF uses fewer and lower doses of fertility medications, reducing medication costs from $3,000-5,000 to a fraction of that amount while also decreasing the risk of ovarian hyperstimulation syndrome. Oma pairs this lower-cost clinical model with efficient clinic operations, transparent pricing, and subscription plans that make ongoing IVF cycles economically sustainable for patients who might otherwise not afford conventional IVF. The company has raised $40M and operates multiple clinic locations primarily in the Midwest and Southeast United States, targeting the large population of fertility patients who are priced out of conventional IVF at $20,000+ per cycle. Oma Fertility has positioned itself in the value segment of the fertility clinic market, complementing premium networks like Kindbody by serving cost-conscious patients who prioritize affordability and accessibility over premium clinic amenities.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.